This was also the case when treating mixed cultures of EGFR- and ErbB2-expressing cancer cells that served as a model for heterogeneous target antigen expression, which is often observed in solid tumors and can contribute to their escape from immunotherapy [56,57]. This evidence concerns the gene ERBB2 and cancer.